

# Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities

Jian Lin <sup>1</sup>, Yuting Dai,<sup>2</sup> Chen Sang,<sup>3</sup> Guohe Song,<sup>3</sup> Bin Xiang,<sup>4</sup> Mao Zhang,<sup>3</sup> Liangqing Dong,<sup>3</sup> Xiaoli Xia,<sup>2</sup> Jiaqiang Ma,<sup>3</sup> Xia Shen,<sup>1</sup> Shuyi Ji,<sup>1</sup> Shu Zhang,<sup>3</sup> Mingjie Wang,<sup>5</sup> Hai Fang,<sup>2</sup> Xiaoming Zhang,<sup>6</sup> Xiangdong Wang,<sup>1</sup> Bing Zhang,<sup>7</sup> Jian Zhou,<sup>3,8</sup> Jia Fan,<sup>3,8</sup> Hu Zhou <sup>9</sup>, Daming Gao,<sup>10</sup> Qiang Gao<sup>1,3,8</sup>

**To cite:** Lin J, Dai Y, Sang C, *et al.* Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities. *Journal for ImmunoTherapy of Cancer* 2022;**10**:e004892. doi:10.1136/jitc-2022-004892

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jitc-2022-004892>).

JL, YD, CS, GS and BX contributed equally.

Accepted 01 July 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

## Correspondence to

Dr Qiang Gao;  
gaoqiang@fudan.edu.cn

Dr Daming Gao;  
dgao@sibcb.ac.cn

Dr Hu Zhou;  
zhouhu@simm.ac.cn

## ABSTRACT

**Background** Immune microenvironment is well recognized as a critical regulator across cancer types, despite its complex roles in different disease conditions. Intrahepatic cholangiocarcinoma (iCCA) is characterized by a tumor-reactive milieu, emphasizing a deep insight into its immunogenomic profile to provide prognostic and therapeutic implications.

**Methods** We performed genomic, transcriptomic, and proteomic characterization of 255 paired iCCA and adjacent liver tissues. We validated our findings through H&E staining (n=177), multiplex immunostaining (n=188), single-cell RNA sequencing (scRNA-seq) (n=10), *in vitro* functional studies, and *in vivo* transposon-based mouse models.

**Results** Integrated multimodule data identified three immune subgroups with distinct clinical, genetic, and molecular features, designated as IG1 (immune-suppressive, 25.1%), IG2 (immune-exclusion, 42.7%), and IG3 (immune-activated, 32.2%). IG1 was characterized by excessive infiltration of neutrophils and immature dendritic cells (DCs). The hallmark of IG2 was the relatively higher tumor-proliferative activity and tumor purity. IG3 exhibited an enrichment of adaptive immune cells, natural killer cells, and activated DCs. These immune subgroups were significantly associated with prognosis and validated in two independent cohorts. Tumors with *KRAS* mutations were enriched in IG1 and associated with myeloid inflammation-dominated immunosuppression. Although tumor mutation burden was relatively higher in IG2, loss of heterozygosity in human leucocyte antigen and defects in antigen presentation undermined the recognition of neoantigens, contributing to immune-exclusion behavior. Pathological analysis confirmed that tumor-infiltrating lymphocytes and tertiary lymphoid structures were both predominant in IG3. Hepatitis B virus (HBV)-related samples tended to be under-represented in IG1, and scRNA-seq analyses implied that HBV infection indeed alleviated myeloid inflammation and reinvigorated antitumor immunity.

**Conclusions** Our study elucidates that the immunogenomic traits of iCCA are intrinsically heterogeneous among patients, posing great challenge

## WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Intrahepatic cholangiocarcinoma (iCCA) represents the second most common type of primary liver cancer, which is generally featured by a highly desmoplastic tumor microenvironment (TME). Sequencing efforts have improved the understanding of the molecular pathogenesis of iCCA; however, the comprehensive landscape of iCCA microenvironment phenotype remains largely unexplored.

## WHAT THIS STUDY ADDS

⇒ Our multimodule study reveals three distinct immune subgroups (IG1, IG2, and IG3) with specific immunological and non-immune profiles associated with different patient outcomes. Myeloid inflammation/*KRAS* mutation, antigen presentation/proliferation, and immune checkpoint could serve as potential therapeutic targets for the treatments of IG1, IG2, and IG3-related iCCA, respectively. Hepatitis B virus (HBV) infection could probably alleviate myeloid inflammation in iCCA, thus activates antitumor immunity and improves the efficacy of immunotherapies.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ These findings extend our understanding of the immunological profile of iCCA. Defined immune subgroups provide novel insights into the heterogeneous TME and underlying therapeutic strategies.

and opportunity for the application of personalized immunotherapy.

## INTRODUCTION

Intrahepatic cholangiocarcinoma (iCCA) accounts for 10%–15% of all primary liver cancer, with a gradual increase over the past decades.<sup>1</sup> Despite the high postoperative recurrence rate, surgery is prior for patients diagnosed at an early stage. Unfortunately,

most patients are diagnosed at advanced stages, when only palliative chemotherapy is available, with a median survival shorter than 12 months. Emerging molecular targeted therapies against *FGFR2* fusion and *IDH1/2* mutations show modest survival benefits in a limited subgroup of patients with iCCA.<sup>2</sup> Hence, identification of novel and effective therapeutics remains an urgent need.

In general, iCCA is featured by a highly desmoplastic tumor microenvironment (TME) with excessively infiltrating immune and stromal cells. Available evidence indicates that the inflammatory microenvironment is associated with iCCA progression and poor prognosis,<sup>3</sup> highlighting TME as a potential target for the treatment of iCCA. Indeed, recent phase II/III clinical trials confirm that immune checkpoint inhibitors (ICIs) plus chemotherapy is promising in patients with iCCA.<sup>4,5</sup> However, the responses and survival benefits are only limited to a small subset of patients, probably owing to the heterogeneous and complex TME. Therefore, a better understanding of the immunogenomic profile is urgently needed for designing novel immunotherapies to improve responses and patient outcomes.

Patient stratification based on immune profile can help delineate immunologically heterogeneous tumors and identify suitable patients for immunotherapy.<sup>6,7</sup> We and others have applied bulk-tumor transcriptomic or proteomic profiles to define clinically relevant iCCA subtypes,<sup>8–13</sup> collectively converging on intertumor immune heterogeneity. Nevertheless, the underlying cancer-cell-intrinsic properties that dictate the diversity in immune landscape remain less characterized. Integrated multidimensional and multimodule analyses of preclinical models and patient samples are needed and expected to deeply characterize the immunological portraits and identify novel personalized immunotherapeutic opportunities in each molecular subtype of iCCA.

In this study, we analyzed the transcriptomic profiles of TME using the largest single-centered iCCA cohort and classified 255 patients into three immune subgroups (IG1, IG2, IG3). By integrating multiple complementary approaches, including whole-exome sequencing (WES), proteomics, single-cell RNA sequencing (scRNA-seq), immunostaining, and mouse models, we delineated the distinct genetic and molecular features among these subgroups. IG1 was an immune-suppressed subgroup with the worst prognosis, harboring the highest myeloid infiltration and *KRAS* mutations; IG2 was characterized by tumor proliferation and antigen presentation defects; IG3 was featured by the activation of antitumor immunity and enrichment of tertiary lymphoid structures (TLSs), with a good prognosis. The substantial differences in immunological profile suggested that each immune subgroup need specific therapeutic strategies.

## METHODS

The iCCA samples from 255 patients used for this study were collected from Zhongshan Hospital of Fudan

University. Patients treated between December 2014 to October 2018 were randomly selected from our prospectively collected tissue bank. Detailed clinicopathological features are summarized in online supplemental table S1.


Full details of multi-omics analysis, multiplexed immunostaining of tissue microarray (TMA), pathological examination, mouse model construction, scRNA-seq analysis, functional experiments, and statistical analysis are provided in the online supplemental materials and methods.

## RESULTS

### Immune-centered classification of iCCA

To characterize the immune profile of iCCA with prognostic significance, multi-omics data derived from the Fudan University (FU-iCCA) cohort (n=255) were obtained (online supplemental figure S1A and online supplemental table S1).<sup>11</sup> Consistent with iCCA's inflammatory and desmoplastic features, our cohort had a relatively higher immune infiltration among The Cancer Genome Atlas (TCGA) Pan-Cancer datasets (online supplemental figure S1B). Unsupervised hierarchical clustering based on the mRNA levels of 170 prognostic genes from TME signature<sup>14</sup> revealed three Immune subGroups, namely IG1, IG2, and IG3 (figure 1A; online supplemental figure S1C–E and online supplemental table S1). Pairing the transcriptomic and proteomic data from this signature created 103 mRNA–protein pairs, which showed an overall positive correlation (median  $r=0.6$ , multiple-test adjusted  $p<0.01$ ; online supplemental figure S1F). Of note, the abundance of corresponding 103 proteins also clustered these patients into similar immune subgroups with a comparable overlap (online supplemental figure S1G).

As expected, the immune subgroups significantly differed in overall survival ( $p=1e-09$ , log-rank test) and recurrence-free survival ( $p=4e-07$ , log-rank test), where IG1 had the worst and IG3 showed the best prognosis (figure 1B). Multivariable Cox analysis further authenticated the immune subgroups as a significantly independent prognosticator (HR, 2.4; 95% CI, 1.33 to 4.5;  $p=4e-03$ ; figure 1C). Carbohydrate antigen 19-9 (CA19-9,  $p=6.8e-11$ ) and carcinoembryonic antigen (CEA,  $p=1.2e-06$ ) were significantly higher in IG1, whereas albumin (ALB,  $p=9.9e-03$ ) levels increased gradually from IG1 to IG3 (online supplemental figure S1H). IG1 had more tumors with necrosis ( $p=0.012$ ) and advanced tumor node metastases (TNM) stage ( $p=2.7e-04$ ) (figure 1D and online supplemental figure S1H). Of note, lymph node metastasis ( $p=0.019$ ) and vascular invasion ( $p=0.038$ ) were predominated in IG1, whereas endothelial cells were enriched in IG3. Increased lymphangiogenesis and reduced angiogenesis could make iCCA more invasive and impair treatment efficacy.<sup>15</sup> Thus, immunostaining confirmed that compared with IG3, where extensive CD31+ blood vessels were observed, IG1 showed a marked



**Figure 1** Immune-centered classification of intrahepatic cholangiocarcinoma (iCCA). (A) Unsupervised hierarchical clustering of the Fudan University (FU)-iCCA ( $n=255$ ) cohort based on the 170 genes. The enriched pathways in IG1 and IG3 were shown on the right ( $\chi^2$  test and adjusted analysis of variance (ANOVA)). (B) Kaplan-Meier curves for overall survival (upper panel) and recurrence-free survival (bottom panel) among the three immune subgroups (log-rank test). (C) HR and p values of immune subgroups and covariates in multivariate analysis for overall survival. (D) The relative abundance of tumor microenvironment (TME) subsets identified from xCell (Fisher's exact test or ANOVA). (E) Univariate analysis for overall survival of each cell subset. (F) Pathological tumor-infiltrating lymphocyte (TIL) estimates ( $n=177$ ) plotted for each tumor sample against indicated signatures. (G) Representative immunostaining images showing the indicated immune subsets. (H) Quantification of staining intensities for the indicated immune markers ( $n=188$ , ANOVA).

increase in podoplanin positive (PDPN+) lymphatic vessels (online supplemental figure S11).

Within this prognostic TME signature, IG1 was enriched with pathways of neutrophil degranulation and epithelial-mesenchymal transition (EMT), suggesting an inflammatory and invasive phenotype. In contrast,

leucocyte-mediated cytotoxicity and lymphocyte-mediated immunity pathways were predominant in IG3, indicating an immune-active milieu (figure 1A). As expected, xCell<sup>14</sup> deconvolution of the RNA-seq data showed that IG1 was dominant by myeloid cells such as neutrophils and immature DCs (iDC), whereas IG3 was abundant in adaptive



immune cells, natural killer (NK) cells, and activated DCs (aDC). Immune infiltration in IG2 was relatively low and heterogeneous, accompanied by the scarcity of stromal cells, which might account for the highest tumor purity ( $p=2.2e-04$ ; [figure 1D](#)). Generally, the abundance of neutrophils ( $p=0.011$ ) and iDC ( $p=0.045$ ) predicted poor survival, whereas the accumulations of lymphocytes, such as CD4+ T cells, CD8+ T effector/memory (Tem) cells, and B cells, were associated with good prognosis (log-rank test; [figure 1E](#)).

Further pathological examination confirmed that tumors in IG3 contained more tumor-infiltrating lymphocyte (TIL) estimates ([figure 1D](#); online supplemental figure S1J,K and online supplemental table S1). Indeed, TIL estimates correlated negatively with tumor purity ( $p=5.3e-03$ ) and positively with immune deconvolution (CD8+ T,  $p=1.6e-06$ ; CD4+ T,  $p=5.6e-05$ ; B cell,  $p=3.8e-04$ ; [figure 1F](#)). Similarly, multiplex immunostaining on TMAs confirmed that the intensities of CD15, CD66b, and CD1a were the strongest in IG1, whereas CD3, CD8, and CD20 were primarily expressed in IG3 ([figure 1G and H](#); online supplemental figure 1L and online supplemental table S1), remarkably consistent with the xCell estimation.

We then performed unsupervised clustering based on the overall mRNAs with the top 25% median absolute deviation and identified three subgroups that were somehow concordant with the immune subgroups ([figure 1A](#)). Specifically, pairing immune subgroups and overall mRNA subgroups (RGs) showed that IG1 and IG3 highly overlapped with RG1 and RG2, respectively. Leveraging our TME gene signature, we also classified Jusakul *et al*'s and Job *et al*'s iCCA cohorts and observed similar patient subgrouping and survival stratification (online supplemental figure 2A–D). Likewise, clustering our RNA-seq data with the transcriptomic signatures from four previous studies<sup>8–10,12</sup> resulted in a significant concordant patient allocation (online supplemental figure 2E–H).

### Distinct molecular features among the three immune subgroups

To further illustrate the key biological processes in patient subgroups, we performed single sample Gene Set Enrichment Analysis (GSEA) using the 50 hallmark gene sets<sup>16</sup> (online supplemental figure S3A and online supplemental table S2). Analysis of principal-component feature showed that PC1 could be explained by tumor purity with immune and stromal gene set vectors opposite to oncogenic and other vectors, whereas PC2 discriminated immune from stromal gene sets (online supplemental figure S3A–C). Unsupervised hierarchical clustering further verified the association between signaling pathways and immune subgroups, as well as separated clustering of immune and other gene sets (online supplemental figure S3D).


Pathway enrichment analysis incorporating both transcriptomics and proteomics data demonstrated distinct molecular features among the immune subgroups

([figure 2A](#)). IG1 was high in inflammatory response, interleukin 6 (IL-6)/janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) signaling, and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ )/nuclear factor kappa-B (NF- $\kappa$ B) signaling, indicating that these tumors may be driven by smoldering inflammation. Hypoxia and glycolysis pathways, which have been implicated in myeloid cell-mediated tumor immune evasions,<sup>17,18</sup> were also predominant in IG1. IG2 were characterized by enrichment of cell-cycle transcriptional programs (G2M checkpoint, E2F targets, Myc targets) and DNA repair pathway, demonstrating the high proliferative activity. Considering the highest tumor burden in IG2, we adjusted the tumor purity<sup>19</sup> and still found enriched proliferation-associated pathways in IG2 (online supplemental figure S3E and online supplemental table S2). IG3 was associated with downregulation of glycolysis and hypoxia pathways, as well as upregulation of the oxidative phosphorylation (OXPHOS) pathway, which has been highlighted as the critical aspects of immune activation<sup>20</sup> ([figure 2A](#)).

We further focused on cancer-promoting and cancer-inhibitory inflammation. IG1 was enriched in protumor inflammatory cytokines and chemokines, including IL-1A, IL-1B, IL-6, CXCL3, CXCL5, and CCL18 ([figure 2B](#)). The mRNA and protein levels of most S100A family members, including S100A8/A9, were upregulated in IG1, which may be involved in cancer-promoting inflammation<sup>21</sup> ([figure 2C](#)). Concurrently, increased mRNA and protein levels of CD8A, GZMA, and PRF1 confirmed the upregulation of cancer-inhibitory inflammation in IG3 ([figure 2B](#)). Moreover, a panel of immune signatures<sup>18,22–24</sup> collectively showed that IG3 displayed elevated T-cell survival and T-effector signatures relative to other subgroups, whereas IG1 exhibited elevated myeloid-derived suppressor cells (MDSC), M2/M1 macrophage, myeloid inflammation, and proinflammation signatures ([figure 2D](#) and online supplemental table S2). Overall, our stratification identified two immune subgroups with antagonistic inflammatory phenotypes.

Recently, the cyclooxygenase 2 (COX-2)/prostaglandin E2 (PGE2) axis has been reported to be involved in regulating the antagonistic inflammatory phenotypes in a Pan-Cancer study.<sup>25</sup> Indeed, the transcript levels of *PTGS2*, encoding for COX-2, were significantly upregulated in IG1 ([figure 2B,E](#)), consistent with the excessive infiltration of PGE2-associated neutrophils and iDCs.<sup>26,27</sup> As expected, patients with higher COX-2 mRNA levels had a worse prognosis ( $p=1e-04$ , log-rank test; [figure 2F](#)). Strong positive correlations between COX-2 mRNA levels and cancer-promoting factors<sup>28</sup> including IL-1A, IL-1B, and IL-6 were detected ([figure 2G](#) and online supplemental table S2). Infiltration of neutrophils and iDCs positively correlated with COX-2 mRNA level, whereas plasma cells, CD4+ T cells, and CD8+ Tem cells showed negative correlations ([figure 2H](#) and online supplemental table S2). The COX-2-associated inflammatory signature (COX-IS) was a predictor for response to ICIs in multiple cancers,<sup>28</sup> and COX-IS decreased sequentially from IG1 to IG3 (online






**Figure 2** Distinct molecular features among the three immune subgroups. (A) Altered pathways at transcriptome and proteome levels among the three immune subgroups. (B) Heatmaps depicting mRNA and protein levels of various markers involved in cancer-promoting or cancer-inhibitory inflammation (adjusted analysis of variance (ANOVA)). (C) Heatmaps depicting mRNA and protein levels of S100A family members (adjusted ANOVA). (D) Signature scores among the three immune subgroups (adjusted ANOVA). (E) Comparisons of COX-2 mRNA levels among the three immune subgroups (Wilcoxon rank-sum test). (F) Kaplan-Meier curves for overall survival based on mRNA abundance of COX-2 (log-rank test). (G and H) Pearson correlation coefficient of COX-2 mRNA level with COX-2-associated inflammatory signature (COX-IS) genes (G) and the xCELL enrichment scores of indicated cell subtypes (H).

supplemental figure S3F). Additionally, IG3 had the highest cytolytic score<sup>29</sup> and immunophenoscore<sup>30</sup> (online supplemental figure S3G,H), further supporting the hypothesis that IG3 could be more likely to respond to ICIs.

### **KRAS mutation-associated myeloid inflammation was dominant in IG1**

We further investigated genomic alterations that could be associated with immunological features. IG2 had

more frequent somatic copy number variations (SCNAs) (online supplemental figure S4A), in agreement with previous reports that SCNA burden negatively correlated with immune cell infiltration<sup>31</sup> (online supplemental figure S4B). When selecting subtype-specific mutated genes, we found that nearly half of tumors in IG1 were *KRAS* mutants (figure 3A,B and online supplemental table S3). *KRAS* mutation was negatively associated with



**Figure 3** The association between *KRAS* mutation and myeloid inflammation. (A) Genes with significant differences in mutational frequency among the three immune subgroups (Fisher's exact test). (B) Somatic variants along *KRAS* protein in the Fudan University-intrahepatic cholangiocarcinoma (FU-iCCA) cohort. (C) Association between mutation profiles and immune/stromal signatures from xCell. Only significantly associations were shown (Wilcoxon rank-sum test). (D) Pathway enrichment analysis based on differentially expressed genes (left panel) and proteins (right panel) that associated with *KRAS* mutations. (E,F) *COX-2* mRNA level (E) and myeloid inflammation score (F) in tumor samples with and without *KRAS* mutation (Wilcoxon rank-sum test). (G,H) Immunohistochemistry of *COX-2*, *Ly6G*, *S100A8*, and *S100A9* (G) and quantification of their staining intensities (H). Representative data of triplicate experiments (mean±SEM). Scale bar, 100 μm. (I) Boxplot showing the fractions of indicated tumor microenvironment (TME) composition in AY (n=6) and AYK (n=6) tumors (analysis of variance (ANOVA)). (J) Violin plot showing the exhausted score in T/natural killer (NK) cells (left panel) and myeloid inflammation and *s100a8/s100a9* expression in neutrophils (right panel) in AY and AYK samples (ANOVA).

most xCell-derived adaptive immune and NK cell signatures, but positively correlated with iDC and neutrophil signatures (figure 3C and online supplemental table S3). GSEA at mRNA and protein levels both identified neutrophil degranulation to be the pathway most

strongly associated with *KRAS* mutation (figure 3D and online supplemental table S3). Consistent with previous report,<sup>32</sup> *KRAS* mutation significantly and positively correlated with several inflammatory molecules, such as *COX-2*, *IL-1A*, *IL-1B*, *IL-6*, and *S100A8/A9*, resembling

the immunological feature of IG1 (figure 3E and online supplemental figure S4C). Tumors with *KRAS* mutation also displayed elevated myeloid inflammatory, COX-1S, and MDSC signatures, as well as decreased cytolytic signature (figure 3F, online supplemental figure 4D–F and online supplemental table S3). In Jusakul's cohort,<sup>33</sup> *KRAS* mutation also led to elevated neutrophil infiltration, COX-2/S100A8 expression, and neutrophil degranulation pathway (online supplemental figure S4G–J).

Considering that *PTGS2* was the most significantly upregulated gene associated with myeloid inflammation both in IG1 and *KRAS* mutant tumors, we hypothesized that *KRAS* mutation may upregulate COX-2 to produce PGE2, which promoted myeloid inflammation. Indeed, ectopic expression of *KRAS*<sup>G12D</sup> in iCCA cells significantly upregulated the mRNA and protein levels of COX-2 and COX-1, as well as increased PGE2 levels in the culture supernatant (online supplemental figure 4K–O). Transwell assay revealed that, compared with *KRAS*<sup>WT</sup>, the culture supernatants from *KRAS*<sup>G12D</sup> significantly enhanced neutrophil migration (online supplemental figure S4P), which could be hampered by COX-2 inhibitor, celecoxib (online supplemental figure S4Q). *KRAS*<sup>G12D</sup> culture supernatant-treated neutrophils showed stronger immunosuppressive activity, as assessed by IL-2 production and apoptosis of preactivated Jurkat T cells (online supplemental figure S4R,S).

We next generated iCCA mouse models using oncogenic drivers myr-AKT and YAP<sup>S127A</sup> in combination with *KRAS*<sup>WT</sup> (AY) or *KRAS*<sup>G12D</sup> (AYK) via the sleeping beauty system and hydrodynamic tail vein injection<sup>34</sup> (online supplemental figure S5A). Immunohistochemistry confirmed that AYK, but not AY tumors, were conspicuously infiltrated with neutrophils (positive for Ly6G, S100A8, and S100A9), while devoid of CD8+ T cells and B cells (figure 3G,H and online supplemental figure S5B,C). scRNA-seq analyses revealed that the proportions of neutrophil and macrophage were significantly higher in AYK tumors, whereas T/NK cells, B cell, and stromal cells were more abundant in AY tumors, consistent with multi-omics' results (figure 3I and online supplemental figure 5D–F). Neutrophils in AYK tumors showed higher myeloid inflammation and elevated expression of inflammatory markers like *S100a8*, *S100a9*, *Ptgs2*, and *Il1b*, accompanied by stronger exhausted phenotypes of T/NK cells (figure 3J and online supplemental figure S5G). Of note, *KRAS* mutation upregulated the expression of COX-2 both in tumor cells and the microenvironment (figure 3G,H and online supplemental figure S5G). Thus, excessive infiltration of neutrophils may account for *KRAS* mutation-associated myeloid inflammation. Overall, *KRAS* mutation had a critical role in subverting anti-tumor immunity to myeloid inflammation-associated immunosuppression (online supplemental figure S5H).


### Antigen presentation defects are associated with immune exclusion in IG2

Defects in antigen presentation could interrupt neoantigen recognition and lead to tumor immune evasion, irrespective of tumor mutation burden (TMB). We thus explored the underlying roles of these avenues of immune evasion among the three immune subgroups (figure 4A). Despite relatively higher TMB and tumor neoantigen burden (TNB) in IG2, defects in antigen presentation through loss of heterozygosity in human leucocyte antigen (HLA LOH,  $p=2e-03$ ) or alterations of the other components of antigen presentation machinery (APM,  $p=0.065$ ) were frequently observed in IG2 (figure 4A,B; online supplemental figure S6A and online supplemental table S4). Such defects may hamper the cross-priming of naive T cells and subsequent tumor recognition by primed T cells, which may explain the reduction in T cell receptor/B cell receptor (TCR/BCR) diversity and RNA-seq reads mapping to VDJ loci in IG2 (online supplemental figure 6B–D).

We further calculated the immunoediting score for each tumor by quantifying the ratio of observed to expected numbers of predicted HLA class-I binding neoantigens, with a score of <1 indicating the presence of immunoediting.<sup>35</sup> Immunoediting scores decreased continuously from IG1 to IG3 (figure 4C and online supplemental table S4). Within each immune subgroup, only IG2 tumors with HLA LOH had a significantly higher immunoediting score, suggesting that tumor subclones in IG2 may be prone to HLA LOH-associated immune evasion (figure 4D). Overall, 15% ( $n=38$ ) of patients exhibited HLA LOH, which had decreasing trends of overall survival ( $p=0.069$ , log-rank test) and recurrence-free survival ( $p=0.024$ , log-rank test) compared with the HLA intact patients (figure 4E,F).

The expression of immune checkpoints may reflect a cancer-adaptive immune response to an active immune system. We found a subgroup-specific pattern of these molecules, where IG2 had relatively few exclusively upregulated immune checkpoints (online supplemental figure S6E). HLA LOH correlated with some immune checkpoint molecules, such as programmed death ligand 1, and refined TMB as a biomarker of ICIs.<sup>36</sup> Comparing the multi-omics profiles between tumors with and without HLA LOH revealed differentially expressed mRNA and proteins that regulated metabolic reprogramming, cell-cycle transcriptional programs, and immune processes. HLA LOH was enriched with higher TMB/TNB, higher tumor purity, decreased interferon gamma pathway, and decreased major histocompatibility complex class I signatures. Likewise, T-cell survival and T-effector signatures were significantly reduced in tumors with HLA LOH (online supplemental figure S6F). Therefore, APM defects, especially HLA LOH, might involve in immune anergy and afterwards immune-exclusion despite the relatively high TMB in IG2 (figure 4G).






**Figure 4** Antigen presentation defects occur frequently in IG2. (A) Antigen presentation machinery (APM) defects in each immune subgroup (Pearson's  $\chi^2$  test or Fisher's exact test). (B,C) Comparison of tumor mutation burden (TMB) (B) and immunoeediting score (C) among the three immune subgroups (Wilcoxon rank-sum test). (D) Immunoeediting score were plotted by HLA LOH status and immune classification (Wilcoxon rank-sum test). (E,F) Kaplan-Meier curves for overall survival (E) and recurrence-free survival (F) based on loss of heterozygosity in human leukocyte antigen (HLA LOH) status (log-rank test). (G) Model illustrating how HLA LOH may lead to immune escape in IG2.

### Tertiary lymphoid structures are related to antitumor immunity in IG3

TLSs provide a pivotal microenvironment for generating antitumor immune responses. We used a previous TLS signature<sup>37</sup> to estimate TLS distribution and found that the mRNA levels of those genes, together with estimated TLS scores, were relatively upregulated in IG3 (figure 5A,B and online supplemental table S5). Pathological examination also confirmed that intratumoral TLSs were significantly accumulated in IG3 (figure 5C,D). Patients with both primary follicles (FL-I)

and secondary follicles (FL-II) had higher estimated TLS scores compared with those with only Aggregates (Agg) and no TLSs (TLSs-), confirming the accuracy of TLS score (figure 5E and online supplemental figure S7A). Consistent with our latest report,<sup>38</sup> intratumoral TLSs predicted a better prognosis (figure 5F-H), and TLSs+ (Agg, FL-I, and FL-II) patients were characterized by early TNM stage ( $p=0.018$ ), lack of microvascular invasion ( $p=0.033$ ), absence of intrahepatic metastasis ( $p=0.011$ ), and small tumor size ( $p=8.1 \times 10^{-4}$ ; online supplemental figure S7A and online supplemental table S5).



**Figure 5** Tertiary lymphoid structures (TLSs) are enriched in IG3. (A) TLS-associated features in each immune subgroup (adjusted analysis of variance (ANOVA)). (B) Comparison of TLS scores among the three immune subgroups (Wilcoxon rank-sum test). (C) Histological appearance of intratumoral TLSs. (D) Comparison of H&E based intratumoral TLS maturation degrees among the three immune subgroups (Fisher's exact test). (E) Comparison of TLS scores among H&E-based intratumoral TLS maturation degrees (Wilcoxon rank-sum test). (F–H) Kaplan-Meier curves for overall survival based on TLS score (F), H&E-based intratumoral TLSs (G), and H&E based intratumoral TLS maturation degrees (H) (log-rank test). (I) Diagram showing the multi-omics profiles of regulators of TLS formation and function.

Multi-omics data indicated that TLSs+ tumors showed specific downregulation of pathways of G2M checkpoint, inflammatory response, and EMT, whereas upregulated ones in metabolism and peroxisome (online supplemental figure S7A). As expected, T cells and B cells, as well as coinhibitors, were enriched in TLSs+ tumors, suggesting an immune-activated phenotype (online

supplemental figure S7B,C). Moreover, both cytolytic scores and COX-1S predicted a better response to immunotherapy for TLSs+ iCCA patients (online supplemental figure S7D,E). Thus, immunosurveillance in IG3 might be partially attributed to intratumoral TLSs (figure 5I), which predicted a better response to immunotherapy in this subgroup.

## HBV infection is negatively associated with myeloid inflammation in iCCA

Hepatitis B virus (HBV) infection is the well-known risk factor for iCCA; however, little is known about the immunogenomic profile of HBV-related iCCA. We found that patients with HBV infection (n=68) were under-represented in IG1 ( $p=0.022$ ), mutually exclusive with *KRAS* mutation ( $p=3.3e-03$ ) and coexisted with *TP53* mutation ( $p=0.036$ ) (figure 6A; online supplemental figure S8A and online supplemental table S6). HBV-positive tumors displayed an elevated cytolytic score, decreased myeloid inflammation signature and decreased COX-2 mRNA levels (figure 6B). Recent study proposed that ICIs showed efficacy for patients with HBV-positive hepatocellular carcinoma (HCC), rather than non-viral HCC.<sup>39</sup> Considering the negative impact of myeloid inflammation on immunotherapy,<sup>40</sup> the COX-2 score predicted worse responses to ICIs in HBV-negative subgroup (figure 6B). The transcriptome of patients with HBV-positive iCCA resembled the expression profile of other solid tumors that responded to ICIs<sup>41</sup> (figure 6C). Thus, the decreased myeloid inflammation observed in HBV-positive iCCA may define a population that could benefit from ICIs.

We additionally collected tumors and adjacent nontumor tissues from five HBV-positive and five HBV-negative iCCAs for scRNA-seq analyses (online supplemental figures S1A and S8B). Increased proportions of T/B/NK cells and reduced proportions of myeloid cells were observed in HBV-positive tumors (figure 6D), but HBV infection did not impact the proportions of each cluster in adjacent nontumor tissues (data not shown). We then classified the 10 patients into the closest immune subgroups according to the enriched gene sets (online supplemental figure S8C). At the CI of 0.7, four patients were excluded, with one (P06T), three (P03T/P09T/P10T), and two (P13T/P15T) samples grouping into IG1, IG2, and IG3, respectively. P06T, the only one remaining in IG1, was also the only patient with *KRAS* mutation among all the 10 iCCAs. The mRNA levels of inflammatory molecules, including COX-2, *IL1A*, *S100A8*, and *S100A9*, were higher in tumor or myeloid subsets in P06T (online supplemental figure S8D). The mRNA levels of cytolytic molecules, such as *CD8A*, *GZMA*, and *PRF1*, were downregulated in T cells in patient P06T, confirming the immunosuppressive TME in IG1 (online supplemental figure S8D).

Next, we performed unsupervised clustering of T/NK cells and myeloid cells. A total of 13 clusters emerged within T/NK cells (figure 6E and online supplemental figure S8E). The proportions of inflammatory CD4 T<sub>H</sub>17 cluster<sup>42</sup> were significantly higher in IG1, whereas the proportion of cytolytic NK<sub>GNLY</sub> cluster slightly increased from IG1 to IG3 (online supplemental figure S8G). Both CD4<sub>SOCS3</sub><sup>43</sup> and NK<sub>CD160</sub><sup>44</sup> were enriched in HBV-positive tumors, implying that HBV infection alleviated inflammatory responses and enhanced cytolytic activities (figure 6F). The reclustering of myeloid lineage revealed

14 populations (figure 6G and online supplemental figure S8F). Notably, Macro\_IL1B was the myeloid cluster with the most significant decrease in proportion after HBV infection, characterized by the exclusively high expression of *IL1A*, *IL1B*, *IL6*, and *TNF* (figure 6H and online supplemental figure S8F). COX-2 mRNA levels and the proinflammatory signatures were significantly higher in Macro\_IL1B than the other myeloid clusters, demonstrating that Macro\_IL1B was the primary source of myeloid inflammation (figure 6I). Indeed, myeloid cells from HBV-related iCCA showed downregulation of inflammatory pathways, such as complement and coagulation cascades and interferon alpha response (figure 6J). A smaller fraction of cycling cells was observed in HBV-positive than in HBV-negative samples, reflecting the relatively decreased proliferative capacities (figure 6H). Altogether, HBV-positive patients harbored a unique TME, with increased proportions of CD4<sub>SOCS3</sub> and NK<sub>CD160</sub> clusters, and reduced Macro\_IL1B cluster and myeloid cell proliferation, which contributed to anti-tumor immunity.

Differentially expressed gene (DEG) analysis revealed that the top downregulated genes in macrophages of HBV-positive tumors included *CCL13*, *CTSC*, *FCGR2A*, *CIQA*, and *CIQB* (online supplemental figure S8H,I). NK cells in HBV-positive tumors upregulated several cytolytic-related genes, such as *KLRC2*, *GZMK*, and *CXCR6* (online supplemental figure S8J). In HBV-positive tumors, macrophages were characterized by downregulated inflammatory responses, whereas NK cells upregulated cytotoxicity and allograft rejection responses (figure 6K and online supplemental figure S8H–J). Collectively, HBV infection in iCCA may alleviate myeloid inflammation and promote anti-tumor immunity. Hence, HBV infection was slightly associated with longer overall survival in our cohort ( $p=0.091$ , log-rank test; figure 6L), consistent with a previous study.<sup>45</sup>


## DISCUSSION

Tremendous sequencing studies have improved our understanding of the molecular pathogenesis of iCCA.<sup>8–11 33</sup> However, little is known about the immunogenomic profile of iCCA and how to leverage this information to maximize responses to immune therapies. Herein, we provided an immunogenomic characterization of iCCAs, involving WES, RNA-seq, proteomics, scRNA-seq and mouse model analyses that could enable the discovery of novel biological insights and identification of promising targets for precise oncological practice.

We identified three distinct immune subgroups with diverse clinical, immune, genetic, and molecular features. IG1 was defined by the enrichment of neutrophils and iDCs, as well as *KRAS* mutations. *KRAS* mutation is associated with the recruitment of myeloid cells and MDSCs into the TME, which then drives immune suppression.<sup>46</sup> Consistently, *KRAS* mutation may probably be the primary cause of myeloid inflammatory and immunosuppression







**Figure 7** Summary of immunogenomic features of intrahepatic cholangiocarcinoma. Radar charts represented mean Z scores for the molecular features and clinical characteristics describing immune-suppressive, immune-exclusion, and immune-activated subgroups. Therapeutic targets of each subgroup were proposed.

TLs. The immunogenomic features of the three immune subgroups were reproducible in multiple independent cohorts,<sup>12,33</sup> supporting that our classification was suitable and reliable.

Chronic inflammation induced by HBV infection increases the risk of HCC and iCCA. Using high-dimensional CyTOF analysis, Lim *et al.* revealed that HBV-related HCC microenvironment is more immunosuppressive and exhausted than that of non-viral-related HCC.<sup>47</sup> In contrast, we found that HBV infections alleviated myeloid inflammation and enhanced the cytolytic activity of NK cells in iCCA, indicating that this common etiology may lead to distinct microenvironments between

HCC and iCCA. Recently, three randomized phase III clinical trials in more than 1600 patients with advanced HCC revealed that immunotherapy was superior in patients with viral-related HCC.<sup>39</sup> However, it is still unknown whether underlying viral hepatitis impacts on ICIs' response in iCCA. We here proposed that HBV infection in iCCA could counteract the excessive myeloid inflammation and potentially reinvigorate antitumor immunity, probably favoring the efficacy of ICIs. The reduced myeloid inflammation in patients with virus-related iCCA might be due to the selection for KRAS wild type tumors during persistent HBV infection.<sup>48</sup> Another rational explanation is the negative correlation between chronic

HBV infection and innate immune response, especially the function of neutrophils.<sup>49</sup>

Therapeutically, this study aimed to characterize iCCA immune subgroups amenable to specific individualized therapies (figure 7 and online supplemental table S7). IG1 might be responsive to myeloid targeted therapies, such as C-X-C motif chemokine receptor 2 (CXCR2) and colony stimulating factor receptor (CSFR) inhibitors to deplete or reprogram tumor-associated neutrophils and M2 macrophages, respectively. Recent success in selective inhibitors of *KRAS* G12C<sup>50</sup> may spark a renewed enthusiasm in targeting *KRAS* mutations in this immune-suppressive subgroup. IG2 may acquire better outcomes from specific CDK inhibitors, as well as strategies that regulate *HLA* and *APM* transcription. The enrichment of TLSs in IG3 and its potential role in the response to ICIs treatment may help guide clinical application of ICIs. Notably, the three immune subgroups showed distinct expression patterns of immune checkpoints, underscoring the need for personalized ICIs.

Our study had some limitations. The use of a retrospective cohort with varied clinicopathological features and treatments may require further prospective validation. In addition, immunostaining on TMAs for estimating immune cell infiltration was likely to over-represent or under-represent the density or distribution of each immune subset. In conclusion, our integrative multi-module analyses provide a comprehensive understanding of iCCA's immune landscape. The three immune subgroups with specific immune and non-immune profiles may have implications for the design of clinical trials using novel therapeutic strategies in iCCA.

#### Author affiliations

<sup>1</sup>Jinshan Hospital Center for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China

<sup>2</sup>Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

<sup>3</sup>Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai, China

<sup>4</sup>Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Shanghai, China

<sup>5</sup>Department of Gastroenterology & Hepatology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

<sup>6</sup>The Center for Microbes, Development and Health, Key Laboratory of Molecular Virology & Immunology, Institute Pasteur of Shanghai, University of Chinese Academy of Sciences, Shanghai, China

<sup>7</sup>Lester and Sue Smith Breast Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA

<sup>8</sup>Key Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai, China

<sup>9</sup>Department of Analytical Chemistry and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

<sup>10</sup>State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China

**Acknowledgements** We thank Peng Cui, Bing Li, and Zhou Zhang (Burning Rock Biotech) for the assistance in bioinformatics analysis.

**Contributors** Conceptualization: QG, DG, and HZ; Methodology: JL, YD, BX, and QG; Formal analysis: JL, YD, BX, LD, XS, SJ, MW, and HF; Investigation: JL, GS, CS, MZ, XX, JM, and SZ; Resources: QG, DG, HZ, JF, JZ, BZ, XW, and XZ; Data curation: QG, YD, and JL; Writing: JL and QG; Visualization: YD and JL; Supervision, QG; Funding acquisition: QG and JL. QG is responsible for the overall content as guarantor.

**Funding** This work was supported by the National Natural Science Foundation of China (Grants 82130077, 81961128025, and 82103314), Research Projects from the Science and Technology Commission of Shanghai Municipality (Grants 20JC1418900 and 19XD1420700), Jinshan Hospital Flexible Mobile Talent Research Startup Fund (RXRC-2020-1), the Science and Technology Commission of Shanghai Municipality (20JC1418900), and China Postdoctoral Science Foundation (Grant 2020M681181).

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** This study involves human participants and was approved by the Research Ethics Committee of Zhongshan Hospital, and written informed consent was obtained from each patient. Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available in a public, open access repository. Data are available on reasonable request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iDs

Jian Lin <http://orcid.org/0000-0001-6457-7026>

Hu Zhou <http://orcid.org/0000-0001-7006-4737>

#### REFERENCES

- Sung H, Ferlay J, Siegel RL, *et al*. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021;71:209–49.
- Lamarca A, Barriuso J, McNamara MG, *et al*. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. *J Hepatol* 2020;73:170–85.
- Zhou Z, Wang P, Sun R, *et al*. Tumor-Associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3. *J Immunother Cancer* 2021;9:e001946.
- Shi G-M, Jian Z, Fan J, *et al*. Phase II study of lenvatinib in combination with GEMOX chemotherapy for advanced intrahepatic cholangiocarcinoma. *Journal of Clinical Oncology* 2021;39:e16163.
- Imfinzi plus chemotherapy significantly improved overall survival in 1st-line advanced biliary tract cancer in TOPAZ-1 phase III trial at interim analysis, 2021. Available: <https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/imfinzi-improved-survival-in-biliary-tract-cancer.html>
- Sia D, Jiao Y, Martinez-Quetglas I, *et al*. Identification of an Immune-specific class of hepatocellular carcinoma, based on molecular features. *Gastroenterology* 2017;153:812–26.
- Diao P, Jiang Y, Li Y, *et al*. Immune landscape and subtypes in primary resectable oral squamous cell carcinoma: prognostic significance and predictive of therapeutic response. *J Immunother Cancer* 2021;9:e002434.
- Andersen JB, Spee B, Blechacz BR, *et al*. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. *Gastroenterology* 2012;142:1021–31.



- 9 Oishi N, Kumar MR, Roessler S, *et al.* Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. *Hepatology* 2012;56:1792–803.
- 10 Sia D, Hoshida Y, Villanueva A, *et al.* Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. *Gastroenterology* 2013;144:829–40.
- 11 Dong L, Lu D, Chen R, *et al.* Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. *Cancer Cell* 2022;40:70–87.
- 12 Job S, Rapoud D, Dos Santos A, *et al.* Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. *Hepatology* 2020;72:965–81.
- 13 Carapeto F, Bozorgui B, Shroff RT, *et al.* The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. *Hepatology* 2022;75:297–308.
- 14 Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. *Genome Biol* 2017;18:220.
- 15 Carpino G, Cardinale V, Di Giambardino A, *et al.* Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma. *J Hepatol* 2021;75:1377–86.
- 16 Liberzon A, Birger C, Thorvaldsdóttir H, *et al.* The molecular signatures database (MSigDB) hallmark gene set collection. *Cell Syst* 2015;1:417–25.
- 17 Taylor CT, Colgan SP. Regulation of immunity and inflammation by hypoxia in immunological niches. *Nat Rev Immunol* 2017;17:774–85.
- 18 Li W, Tanikawa T, Kryczek I, *et al.* Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer. *Cell Metab* 2018;28:87–103.
- 19 Aran D, Sirota M, Butte AJ. Systematic pan-cancer analysis of tumour purity. *Nat Commun* 2015;6:8971.
- 20 Hornburg M, Desbois M, Lu S, *et al.* Single-Cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. *Cancer Cell* 2021;39:928–44.
- 21 Wang S, Song R, Wang Z, *et al.* S100A8/A9 in inflammation. *Front Immunol* 2018;9:1298.
- 22 Xiao Y, Ma D, Zhao S, *et al.* Multi-Omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer. *Clin Cancer Res* 2019;25:5002–14.
- 23 Petitprez F, de Reyniès A, Keung EZ, *et al.* B cells are associated with survival and immunotherapy response in sarcoma. *Nature* 2020;577:556–60.
- 24 McDermott DF, Huseni MA, Atkins MB, *et al.* Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. *Nat Med* 2018;24:749–57.
- 25 Kawahara K, Hohjoh H, Inazumi T, *et al.* Prostaglandin E2-induced inflammation: relevance of prostaglandin E receptors. *Biochim Biophys Acta* 2015;1851:414–21.
- 26 Wang D, DuBois RN. Role of prostanoids in gastrointestinal cancer. *J Clin Invest* 2018;128:2732–42.
- 27 Dudek AM, Martin S, Garg AD, *et al.* Immature, semi-mature, and fully mature dendritic cells: toward a DC-Cancer cells interface that augments anticancer immunity. *Front Immunol* 2013;4:438.
- 28 Bonavita E, Bromley CP, Jonsson G, *et al.* Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade. *Immunity* 2020;53:1215–29.
- 29 Dufva O, Pölonen P, Brück O, *et al.* Immunogenomic landscape of hematological malignancies. *Cancer Cell* 2020;38:380–99.
- 30 Charoentong P, Finotello F, Angelova M, *et al.* Pan-Cancer Immunogenomic analyses reveal Genotype-ImmunoPhenotype relationships and predictors of response to checkpoint blockade. *Cell Rep* 2017;18:248–62.
- 31 Davoli T, Uno H, Wooten EC, *et al.* Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. *Science* 2017;355:eaaf8399.
- 32 Hamarshah Shaima'a, Groß O, Brummer T, *et al.* Immune modulatory effects of oncogenic KRAS in cancer. *Nat Commun* 2020;11:5439.
- 33 Jusakul A, Cutcutache I, Yong CH, *et al.* Whole-Genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. *Cancer Discov* 2017;7:1116–35.
- 34 Affo S, Nair A, Brundu F, *et al.* Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. *Cancer Cell* 2021;39:866–82.
- 35 Rosenthal R, Cadieux EL, Salgado R, *et al.* Neoantigen-directed immune escape in lung cancer evolution. *Nature* 2019;567:479–85.
- 36 Montesin M, Murugesan K, Jin DX, *et al.* Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. *Cancer Discov* 2021;11:282–92.
- 37 Wang J, Jiang D, Zheng X. Tertiary lymphoid structure and CD8 T cell exclusion in minimally invasive adenocarcinoma. *medRxiv* 2020.
- 38 Ding G-Y, Ma J-Q, Yun J-P, *et al.* Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. *J Hepatol* 2022;76:608–618.
- 39 Pfister D, Núñez NG, Pinyol R, *et al.* Nash limits anti-tumour surveillance in immunotherapy-treated HCC. *Nature* 2021;592:450–6.
- 40 Nakamura K, Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. *Cell Mol Immunol* 2020;17:1–12.
- 41 Montal R, Sia D, Montironi C, *et al.* Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. *J Hepatol* 2020;73:315–27.
- 42 Shen X, Wang Y, Gao F, *et al.* Cd4 T cells promote tissue inflammation via CD40 signaling without de novo activation in a murine model of liver ischemia/reperfusion injury. *Hepatology* 2009;50:1537–46.
- 43 Ding F-M, Liao R-M, Chen Y-Q, *et al.* Upregulation of SOCS3 in lung CD4+ T cells in a mouse model of chronic PA lung infection and suppression of Th17-mediated neutrophil recruitment in exogenous SOCS3 transfer in vitro. *Mol Med Rep* 2017;16:778–86.
- 44 Sun H, Xu J, Huang Q, *et al.* Reduced CD160 expression contributes to impaired NK-cell function and poor clinical outcomes in patients with HCC. *Cancer Res* 2018;78:6581–93.
- 45 Jeong S, Tong Y, Sha M, *et al.* Hepatitis B virus-associated intrahepatic cholangiocarcinoma: a malignancy of distinctive characteristics between hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *Oncotarget* 2017;8:17292–300.
- 46 Pylayeva-Gupta Y, Lee KE, Hajdu CH, *et al.* Oncogenic KRAS-induced GM-CSF production promotes the development of pancreatic neoplasia. *Cancer Cell* 2012;21:836–47.
- 47 Lim CJ, Lee YH, Pan L, *et al.* Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. *Gut* 2019;68:916–27.
- 48 Bose S, Sakhuja P, Bezawada L, *et al.* Hepatocellular carcinoma with persistent hepatitis B virus infection shows unusual downregulation of Ras expression and differential response to Ras mediated signaling. *J Gastroenterol Hepatol* 2011;26:135–44.
- 49 Hu S, Liu X, Gao Y, *et al.* Hepatitis B virus inhibits neutrophil extracellular trap release by modulating reactive oxygen species production and autophagy. *J Immunol* 2019;202:805–15.
- 50 Kim D, Xue JY, Lito P. Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. *Cell* 2020;183:850–9.